Gartner Research

Time for Action on Track and Trace in the Pharmaceutical Supply Chain

Published: 28 February 2013

ID: G00245707

Analyst(s): Todd Applebaum


Pharma manufacturers must begin implementing serialization and track and trace, or risk losing access to the U.S. market. Supply chain leaders at pharma manufacturers can use this research to shift from the wait-and-see approach of 2012 to building a compliant foundation.

Table Of Contents
  • Impacts


Impacts and Recommendations

  • The 2015 and 2016 enforcement dates for California's pedigree law are pushing manufacturers around the world to begin investing now, or risk noncompliance and loss of access to the U.S. market
  • Continued regulatory uncertainty and varied requirements around the world are making it difficult for drug manufacturers to identify compliance requirements and make investments
    • Clarification of Compliance Requirements
    • Timeline for Enforcement
    • Federal Pre-emption
    • Global Requirements
  • Three likely solution models have emerged for interoperable track and trace across the pharmaceutical value chain, and they continue to evolve, placing manufacturers' early investments at risk
    • Document-Centric E-Pedigree
    • PoD Authentication
    • Network-Centric (Full) Track and Trace

Recommended Reading

©2020 Gartner, Inc. and/or its affiliates. All rights reserved. Gartner is a registered trademark of Gartner, Inc. and its affiliates. This publication may not be reproduced or distributed in any form without Gartner’s prior written permission. It consists of the opinions of Gartner’s research organization, which should not be construed as statements of fact. While the information contained in this publication has been obtained from sources believed to be reliable, Gartner disclaims all warranties as to the accuracy, completeness or adequacy of such information. Although Gartner research may address legal and financial issues, Gartner does not provide legal or investment advice and its research should not be construed or used as such. Your access and use of this publication are governed by Gartner’s Usage Policy. Gartner prides itself on its reputation for independence and objectivity. Its research is produced independently by its research organization without input or influence from any third party. For further information, see Guiding Principles on Independence and Objectivity.

Already have a Gartner Account?

Become a client

Learn how to access this content as a Gartner client.